PEG, or polyethylene glycol, is a synthetically constructed polymer, made of repeating units of ethylene glycol (-CH2-CH2-O-). It is known for its properties of being water-soluble, as it is strongly hydrophilic with a large exclusion volume in aqueous solution, and it is also resistant to non-specific protein adsorption. Due to these unique characteristics, PEG has found itself being used in the field of biopharmaceuticals as a coating for drug proteins, peptides, drug-antibody conjugates, aptamers, or monoclonal antibodies to facilitate their delivery.
The special properties of PEG coatings help to overcome the limitations of biopharmaceutical drugs. Also, PEG coatings have the impact of increasing the hydrodynamic size and masking the surface epitopes of the biopharmaceutical drugs, help to reduce immunogenicity.
Antibodysystem PEG series antibody is suitable for WB, FC, ELISA, IHC.
1.PEG antibodies can be used to detect PEG drugs.
2.PEG antibodies play an important role in PK research of PEG drugs.
3.PEG antibodies can also be used for immunogenicity analysis of PEG drugs.
|Product name||Catalog No.||Applications||Host species||Isotype|
|Anti-PEG Antibody (E11.2#)||RGK24701||ELISA, WB||Mouse||IgG1, kappa|
|Anti-PEG Antibody (6A9/PEG.2)||RGK24702||ELISA||Mouse||IgG1, kappa|
|Anti-PEG Antibody (14B5/PEG.1a)||RGK24703||ELISA||Mouse||IgG1, kappa|
|Anti-PEG Antibody (14B5/PEG.1b)||RGK24704||ELISA||Mouse||IgG1, kappa|
|Anti-PEG Antibody (3.3.1)||RGK24705||ELISA, FC||Mouse||IgG1, kappa|
|Anti-PEG Antibody (2B5)||RGK24706||ELISA, FC||Mouse||IgG1, kappa|
|Anti-PEG Antibody (32D6)||RGK24707||ELISA, FC||Mouse||IgG1, kappa|
|Anti-PEG Antibody (AGP3)||RGK24707||ELISA, FC, WB,IHC||Mouse||IgG1, kappa|
|Anti-PEG Antibody (6.3)||RGK24709||ELISA, FC, WB||Mouse||IgG1, kappa|
|Anti-PEG Antibody (15-2b)||RGK24710||ELISA, FC, WB||Mouse||IgG1, kappa|
1.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation PMCID: PMC5747248.
2.Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals PMID: 32745496
3.Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice PMCID: PMC7946756.
4.Anti-PEG immunity: emergence, characteristics, and unaddressed questions PMCID: PMC4515207.